BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.
Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A.
Rustad EH, et al. Among authors: waage a.
Blood Cancer J. 2015 Mar 20;5(3):e299. doi: 10.1038/bcj.2015.24.
Blood Cancer J. 2015.
PMID: 25794135
Free PMC article.